Evaluation of 2,3-dihydroimidazo[2,1-b]oxazole and imidazo[2,1-b]oxazole derivatives as chemotherapeutic agents

被引：1

作者：

Shahin, Afnan, I ^{[1
]}

Zaraei, Seyed-Omar ^{[1
]}

Alzuraiqi, Shahed ^{[2
]}

Abdulateef, Zahaa ^{[2
]}

Abbas, Noora E. ^{[2
]}

Al-Tel, Taleb H. ^{[1
,2
]}

El-Gamal, Mohammed, I ^{[1
,2
,3
]}

机构：

[1] Univ Sharjah, Res Inst Med & Hlth Sci, Sharjah 27272, U Arab Emirates

[2] Univ Sharjah, Coll Pharm, Dept Med Chem, Sharjah 27272, U Arab Emirates

[3] Mansoura Univ, Fac Pharm, Dept Med Chem, Mansoura 35516, Egypt

来源：

FUTURE MEDICINAL CHEMISTRY | 2023年 / 15卷 / 20期

关键词：

2,3-dihydroimidazo[2,1-b]oxazole; anticancer; antimicrobial; delamanid; imidazo[2,1-b]oxazole; tuberculosis; ANTITUBERCULOSIS DRUG; DELAMANID; TOXICITY; INHIBIT; AGONIST;

D O I：

10.4155/fmc-2023-0147

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Imidazo[2,1-b]oxazole and 2,3-dihydroimidazo[2,1-b]oxazole ring systems are commonly employed in therapeutically active molecules. In this article, the authors review the utilization of these core scaffolds as chemotherapeutic agents from 2018 to 2022. These scaffolds possess many important biological activities including antimicrobial and anticancer, among others. This review covers their biological activities and structure-activity relationships. One of the most important drugs in this class of compounds is the antitubercular agent delamanid. In this paper, the compounds structure-activity relationship and preclinical and clinical trial data are thoroughly presented. [GRAPHICS] .

引用

页码：1885 / 1901

页数：17